AbbVie Inc AML Treatment Produces Positive Phase-II Trial Results

December 8, 2014 3:20 AM

4 0

AbbVie Inc announced positive Phase-II trial results for its pipeline drug venetoclax as a treatment for patients with acute myelogenous leukemia

AbbVie Inc (NYSE:ABBV) announced positive Phase-II trial results for its pipeline compound venetoclax as a treatment for acute myelogenous leukemia (AML) at the American Society of Hematology’s (ASH) 56th Annual Meeting session on Sunday. The company spent $3.3 billion in expenses related to researc...

Read more

To category page

Loading...